12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iluvien regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Iluvien fluocinolone acetonide intravitreal implant from Alimera to treat chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Alimera said it is developing a patient access scheme (PAS) to address...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >